Retina

Atsena reported that, since enrollment opened in May 2026, it has already accrued approximately 10% of the pivotal cohort and expects the pace to accelerate as additional sites across North America and Europe are activated.

Utilize oral agents, diet and glucose monitoring systems when acting to preserve vision

New pathways are reshaping the management of retinal disease

Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant, a potential first approved treatment for Stargardt disease type 1.

Retina cells that sense light falter in Alzheimer’s, potentially derailing sleep and body clocks—pointing to new diagnostic and treatment angles.

StemSight secures new patents for scalable induced pluripotent stem cells-derived limbal stem cells, boosting STE-101’s path to off-the-shelf limbal stem cell deficiency therapy and upcoming Series A.

Optical coherence tomography angiography found distinctive microvascular signatures in the retinal layers associated with various stages of decline in cognition.

The update introduces a 250 kHz scan speed for OCT Angiography combined with enhanced TruTrack Active Eye Tracking, as well as new multimodal imaging capabilities, including the Green Autofluorescence Module

Alkeus Pharmaceuticals has dosed the first participant in the phase 3 NORTHSTAR trial of oral gildeuretinol for Stargardt disease, a condition with no approved treatments.

Alkeus Pharmaceuticals has dosed the first participant in the phase 3 NORTHSTAR trial of oral gildeuretinol for Stargardt disease, a condition with no approved treatments.

Finding satisfaction in ocular research—considerations about AI and enhanced datasets.

Samsung Bioepis launched Opuviz, an aflibercept biosimilar, in Europe for wet AMD, DME, retinal vein occlusion, and myopic CNV.

Therini Bio begins a phase 1b DME trial of THN391, an intravitreal antibody targeting fibrin-driven retinal inflammation.

The device, described in a new study, uses a technique called temporal interference-based transcorneal electrical stimulation, or TI-TES.

Transient vision loss may foreshadow stroke or heart events; study urges urgent 90-day evaluation and long-term cardiovascular monitoring.

Swiss regulator backs tinlarebant for Stargardt as DRAGON phase 3 shows slower retinal atrophy, bringing first treatment closer to patients.

Siegfried G. Priglinger, MD, FEBO, weighs in on the emerging rationale for gas-free, position-free macular hole surgery using an ILM flap.

Two leading retinal specialists break down MCO-010's 3-year efficacy and safety data, the significance of contralateral eye findings, and how this gene-agnostic optogenetic approach could fill a critical gap for patients with advanced inherited retinal degeneration who have limited treatment options.

Wireless brain implant taps visual cortex to deliver artificial sight, marking third successful surgery and recruiting volunteers for trials.

Single-shot optogenetic injection restores light sensitivity in advanced retinitis pigmentosa, delivering sustained vision gains for years with strong safety, expanding hope beyond gene-specific therapy.

Learn how IBD affects gut and beyond—risk factors, gender differences, eye complications, and treatment options to manage flares and protect vision.

The novel dual-port cutter, designed for use with the Stellaris Elite platform, offers increased flow rate and reduced cutter vibration.

Data presented at ARVO 2026 show that high-dose gene therapy boosts central retinal sensitivity in X-linked retinitis pigmentosa, with the phase 3 VISTA study fully enrolled.

Phase 2 and phase 3 results in diabetic macular edema and uveitic macular edema support intravitreal anti–IL-6 therapy

Interim 6-month results from Part B of the LIGHTHOUSE trial show structural and functional improvements consistent with earlier cohorts; pivotal Phase 3 enrollment now underway with BLA filing targeted for 2028.